Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 665-670

  Salonen, Kirsi M ^a   Ryhänen, Samppa J ^a   Forbes, Josephine M ^b   Borg, Danielle J ^b   Härkönen, Taina ^a   Ilonen, Jorma ^c,d   Simell, Olli ^c   Veijola, Riitta ^e   Groop, Per Henrik ^a,f,g,h   Knip, Mikael ^a,f,i  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Mater Medical Research Institute   (Australia)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

ⁱ TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAPLOTYPE; HLA TYPING; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SEROCONVERSION; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; DOWN REGULATION; INFANT; NEWBORN; PATHOLOGY; PREDIABETIC STATE;

AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYSINE; MALE; PREDIABETIC STATE; RECEPTORS, IMMUNOLOGIC;

EID: 84930943997     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1186     Document Type: Article

References (37)

1. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010;9:A355-A365.
2. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: A cohort study. Lancet 2008; 371:1777-1782.
3. Patterson CC, Dahlquist GG, Gÿurus E, Green A, Soltesz G; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet 2009;373:2027-2033.
4. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007690.
5. Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. Curr Drug Targets 2012;13:526-540.
6. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) 2009;87:235-247.
7. Piarulli F, Sartore G, Lapolla A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: A clinical update. Acta Diabetol 2013; 50:101-110.
8. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 2012;109:15888-15893.
9. Mark AB, Poulsen MW, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014;37:88-95.
10. Forbes JM, Soderlund J, Yap FY, et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia 2011;54:1032-1042.
11. Beyan H, Riese H, Hawa MI, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: A twin and population study. Diabetes 2012;61: 1192-1198.
12. Coughlan MT, Yap FY, Tong DC, et al. Advanced glycation end products are direct modulators of b-cell function. Diabetes 2011;60: 2523-2532.
13. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003;52:1441-1448.
14. Salonen KM, Ryhanen SJ, Forbes JM, et al.; Finnish Pediatric Diabetes Register. Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes. Diabetes Care 2014;37:1975-1981.
15. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.
16. Nin JW, Ferreira I, Schalkwijk CG, et al.; EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009;52:705-714.
17. Thomas MC, Soderlund J, Lehto M, et al.; FinnDiane Study Group. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011;54:2669-2677.
18. Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.
19. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: A new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009;48:1190-1196.
20. Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007;56:4174-4181.
21. Kupila A, Muona P, Simell T, et al.; Juvenile Diabetes Research Foundation Centre for the Prevention of Type I Diabetes in Finland. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 2001;44:290-297.
22. Coughlan MT, Patel SK, Jerums G, et al. Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. Am J Nephrol 2011;34:347-355.
23. SalonenKM, Ryhanen S, Harkonen T, Ilonen J, Knip M; Finnish Pediatric Diabetes Register. Autoantibodies against zinc transporter 8 are related to age, metabolic state and HLA DR genotype in children with newly diagnosed type 1 diabetes. Diabetes Metab Res Rev 2013;29:646-654.
24. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009;11:R39.
25. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr 2009;48:38-44.
26. Semba RD, Gebauer SK, Baer DJ, et al. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr 2014;144:1037-1042.
27. Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 2014;111:4940-4945.
28. Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 1999;26:343-348.
29. Chiavaroli V, D'Adamo E, Giannini C, et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012;35:1361-1363.
30. Rogers LK, Graf AE, Bhatia A, Leonhart KL, Oza-Frank R. Associations between maternal and infant morbidities and sRAGE within the first week of life in extremely preterm infants. PLoS One 2013;8:e82537.
31. Dettoraki A, Gil AP, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:895-904.
32. Giannini C, D'Adamo E, de Giorgis T, et al. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol 2012;27:269-275.
33. Zorena K, Kula M, Malinowska E, Raczy nska D, Mýsliwiec M, Raczy nska K. Threshold serum concentrations of tumour necrosis factor alpha (TNFa) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Hum Immunol 2013;74:75-81.
34. Skrha J Jr, Kalousova M, Svarcova J, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012;120:277-281.
35. Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med 2013;30:702-709.
36. Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol 2011;38:1994-1999.
37. Bower JK, Pankow JS, Lazo M, et al. Threeyear variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem 2014;47:132- 134.